Basilea successfully places CHF 125 million senior convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN
Basel, Switzerland, June 24, 2020
Basilea Pharmaceutica Ltd. (SIX: BSLN, the “Issuer”) successfully completed the offering of CHF125 million senior unsecured convertible bonds due 2027 (the “Bonds”), fully exercising an increase option of CHF25 million. Such provisional allocation of the increase option remains subject to a pro-rata reduction, subject to the final amount of Outstanding Bonds tendered in the Tender Offer. The offering attracted meaningful demand from domestic and international investors.
With the envisaged issuance of the Bonds, Basilea aims to extend its debt maturity profile and to optimize its debt structure, targeting part of the outstanding senior unsecured convertible bonds due 2022 issued by the Issuer (the "Outstanding Convertible Bonds").
The proceeds from the offering will be used to finance a planned tender offer for the Outstanding Convertible Bonds and for general corporate purposes. In accordance with the Articles of Association, the aggregate principal amount of the Outstanding Convertible Bond and the Bonds will not exceed CHF 250 million upon completion of the transaction.
On the back of the successful pricing and provisional allocation today, Basilea plans to invite all eligible holders of its outstanding senior unsecured convertible bonds due 2022 to tender their Outstanding Convertible Bonds for cash during the tender offer period (the "Tender Offer").The publication of the Tender Offer notice is planned tomorrow, June 25, 2020 and the tender offer period is expected to commence on July 10, 2020 and expire July 16, 2020 at 4pm CEST. This Press Release is not an offer for the repurchase of the Outstanding Convertible Bonds, but only discloses the most important terms of the planned Tender Offer.
The Bonds will have a maturity of seven years and will be convertible into shares sourced from existing conditional capital and existing treasury shares (the “Shares”). Holders of the Bonds will be entitled to request an early redemption of their Bonds on the fifth anniversary of their issue, at 100% of the principal amount. The Bonds will carry a coupon of 3.25% per annum, payable semi-annually in arrear, and have a conversion price set at a premium of 25% over the reference share price, being the placement price per Share in the Delta Placement (as further described below). The Bonds in the denomination of CHF 5,000 will be issued at par and, unless previously converted or repurchased and cancelled, redeemed at 100% of their principal amount.
At the request of the Issuer, the Joint Global Coordinators intend to facilitate sales of Shares by buyers of the Bonds who wish to sell these Shares in short sales, at a placement price to be determined via an accelerated bookbuilding process, to purchasers procured by the Global Coordinators, in order to hedge the market risk to which the buyers of Bonds are exposed with respect to the Bonds (the “Delta Placement”). The Delta Placement is expected to take place within the first four business days after the successful completion of the Tender Offer. The Issuer will not receive any proceeds from any sale of Shares in any such offering.
The Bonds will be provisionally allocated to investors participating in today's bookbuilding. Such provisional allocation of the Bonds remains subject to a pro-rata reduction of the increase option, subject to the final amount of Outstanding Bonds tendered in the Tender Offer.
The final allocation and issuance of the Bonds is subject to the following conditions precedents:
- The Issuer reserves the right not to proceed with the issue of the Bonds if less than CHF 90 million of the aggregate principal amount of the Outstanding Convertible Bonds have been tendered in the planned Tender Offer.
- The Bonds shall not be issued if the setting of the reference share price and Delta Placement have not occurred.
- The Bonds shall not be issued if the conversion price is below CHF 46.9993.
The final terms of the Bonds, with the initial conversion price, are expected to be announced after the Delta Placement, provided the conditions precedents are met or waived. The number of shares to be potentially delivered upon conversion will be determined at pricing and shall be sourced from existing conditional capital and from existing treasury shares.
Basilea intends to make an application for the Bonds to be admitted for listing and trading on the SIX Swiss Exchange with provisional trading expected to start on or about 28th July 2020. Payment and settlement of the Bonds is expected on or about 28th July 2020.
Basilea agreed to a lock-up of 90 days from the payment date, subject to customary exceptions.
Goldman Sachs International and UBS are acting as Joint Global Coordinators and Joint Bookrunners on the offering.
Indicative timeline of the transaction
|24 June 2020|| Launch of the placement of Bonds (“New Issue”)|
Pricing / Allocation of the New Issue (excl. Reference Price)
|25 June 2020||Planned publication of intended Tender Offer|
|16 July 2020||End of the planned Tender Offer (expected to expire at 4pm CEST)|
|Expected on or around 20 July 2020|| Expected Delta Placement, subject to market conditions|
Setting of the reference price
|Expected on 28 July 2020||New Issue Payment Date|
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar notice within the meaning of article 652a, article 752 and/or article 1156 of the Swiss Code of Obligations or within the meaning of the Swiss Financial Services Act or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange. The offer and listing will be made solely by means of, and on the basis of, a securities prospectus which is to be published. An investment decision regarding the publicly offered securities of the Company should only be made on the basis of the securities prospectus. The prospectus is available free of charge at UBS AG, Swiss Prospectus Library, P.O. Box, CH-8098 Zurich (telephone: +41 (0)44 239 47 03, facsimile: +41 (0)44 239 69 14 or email: email@example.com).
This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.
THIS COMMUNICATION IS NOT FOR DISTRIBUTION IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN. THIS COMMUNICATION DOES NOT CONSTITUTE AN OFFER TO SELL, OR THE SOLICITATION OF AN OFFER TO BUY, SECURITIES IN ANY JURISDICTION IN WHICH IS UNLAWFUL TO DO SO. IN PARTICULAR, THIS COMMUNICATION IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION UNDER THE SECURITIES ACT OF 1933 OR AN EXEMPTION FROM REGISTRATION. THE SECURITIES REFERRED TO IN THIS COMMUNICATION HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT AND WILL NOT BE PUBLICLY OFFERED OR SOLD IN THE UNITED STATES.
This communication does not constitute an "offer of securities to the public" within the meaning of Regulation 2017/1129 of the European Union (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Regulation, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.
This communication expressly or implicitly contains certain forward-looking statements concerning the Company and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
|Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CEST | Press release
Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS18.9.2020 16:20:00 CEST | Press release
Sveriges Riksbank Bid procedure details Covered Bonds, 2020-09-24 Maturity dateLoanISIN codeCouponVolume, SEK million2022-04-08 5531 SE00069912461.00 %1,000 +/- 5002022-12-21 575 SE00105465721.50 %1,000 +/- 500 2022-09-211586SE00031748384.50 %1,000 +/- 5002022-06-15191SE00075256541.00 %1,000 +/- 5002022-12-212212SE00102970851.00 %400 +/- 2502022-09-21515SE00072784292.25 %400 +/- 2502022-06-15143SE00085866551.25 %400 +/- 250 Settlement date 2020-09-28 Bids have to be entered by 10.00 on SEP 24, 2020 Highest permitted bid volume: 1,000 SEK million in issue 5531 1,000 SEK million in issue 575 1,000 SEK million in issue 1586 1,000 SEK million in issue 191 400 SEK million in issue 2212 400 SEK million in issue 515 400 SEK million in issue 143 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON SEP 24, 2020. For more information, please con
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.9.2020 16:20:00 CEST | Press release
Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se. Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol
Karolinska Development’s portfolio company OssDsign strengthens patent coverage for OssDsign Cranial PSI in key market18.9.2020 16:04:55 CEST | Press release
STOCKHOLM, SWEDEN – September 18, 2020. Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has received a notice of allowance from the United States Patent and Trademarks Office (USPTO) concerning the implant design for the company’s product Cranial PSI, thus strengthening the patent protection for the technology in the company’s most important market in the US. The patent covers the implant, its support structure, as well as the method of making customized implants for each patient. Approvals of the patent were given in the European and Japanese markets last year and in Australia earlier in 2020. With the allowance in the US, a stronger patent protection for OssDsign Cranial PSI is thus established in all key markets. The patent family is valid until 2035 and builds upon a broad international patent portfolio. “The notice of allowance granted by the USPTO is an important final step in securing the patent protection for the technology behind O
Karolinska Developments portföljbolag OssDsign stärker patentskyddet på huvudmarknad för OssDsign Cranial PSI18.9.2020 16:04:55 CEST | Pressemelding
STOCKHOLM, SVERIGE 18 september 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget OssDsign har givits ett godkännande av det amerikanska patentverket (USPTO) för ett patent relaterat till designen av bolagets produkt Cranial PSI. Genom godkännandet stärks patentskyddet för sin teknologi på bolagets viktigaste marknad USA. Patentet täcker implantatet, dess förstärkande struktur, samt metoden att tillverka ett patientspecifikt implantat. Bolaget erhöll patentskydd för produkten i Europa och Japan under föregående år och i Australien under början av 2020. Med godkännandet från den amerikanska myndigheten har nu bolaget etablerat ett starkt patentskydd för Cranial PSI på samtliga nyckelmarknader. Patentfamiljen, som är giltig till 2035, förstärker OssDsigns redan omfattande internationella patentskydd. ”Godkännandet från USPTO är ett viktigt sista steg för att säkerställa ett patentskydd för teknologin bakom OssDsigns Cranial PSI på alla viktiga mar